366 related articles for article (PubMed ID: 33333023)
1. Structural basis of human monocarboxylate transporter 1 inhibition by anti-cancer drug candidates.
Wang N; Jiang X; Zhang S; Zhu A; Yuan Y; Xu H; Lei J; Yan C
Cell; 2021 Jan; 184(2):370-383.e13. PubMed ID: 33333023
[TBL] [Abstract][Full Text] [Related]
2. Cellular Uptake of MCT1 Inhibitors AR-C155858 and AZD3965 and Their Effects on MCT-Mediated Transport of L-Lactate in Murine 4T1 Breast Tumor Cancer Cells.
Guan X; Rodriguez-Cruz V; Morris ME
AAPS J; 2019 Jan; 21(2):13. PubMed ID: 30617815
[TBL] [Abstract][Full Text] [Related]
3. Monocarboxylate transporter 1 and 4 inhibitors as potential therapeutics for treating solid tumours: A review with structure-activity relationship insights.
Puri S; Juvale K
Eur J Med Chem; 2020 Aug; 199():112393. PubMed ID: 32388280
[TBL] [Abstract][Full Text] [Related]
4. The inhibition of monocarboxylate transporter 2 (MCT2) by AR-C155858 is modulated by the associated ancillary protein.
Ovens MJ; Manoharan C; Wilson MC; Murray CM; Halestrap AP
Biochem J; 2010 Oct; 431(2):217-25. PubMed ID: 20695846
[TBL] [Abstract][Full Text] [Related]
5. Activity of the monocarboxylate transporter 1 inhibitor AZD3965 in small cell lung cancer.
Polański R; Hodgkinson CL; Fusi A; Nonaka D; Priest L; Kelly P; Trapani F; Bishop PW; White A; Critchlow SE; Smith PD; Blackhall F; Dive C; Morrow CJ
Clin Cancer Res; 2014 Feb; 20(4):926-937. PubMed ID: 24277449
[TBL] [Abstract][Full Text] [Related]
6. A Holistic Evolutionary and 3D Pharmacophore Modelling Study Provides Insights into the Metabolism, Function, and Substrate Selectivity of the Human Monocarboxylate Transporter 4 (hMCT4).
Papakonstantinou E; Vlachakis D; Thireou T; Vlachoyiannopoulos PG; Eliopoulos E
Int J Mol Sci; 2021 Mar; 22(6):. PubMed ID: 33805725
[TBL] [Abstract][Full Text] [Related]
7. Identification of key binding site residues of MCT1 for AR-C155858 reveals the molecular basis of its isoform selectivity.
Nancolas B; Sessions RB; Halestrap AP
Biochem J; 2015 Feb; 466(1):177-88. PubMed ID: 25437897
[TBL] [Abstract][Full Text] [Related]
8. The role of charged residues in the transmembrane helices of monocarboxylate transporter 1 and its ancillary protein basigin in determining plasma membrane expression and catalytic activity.
Manoharan C; Wilson MC; Sessions RB; Halestrap AP
Mol Membr Biol; 2006; 23(6):486-98. PubMed ID: 17127621
[TBL] [Abstract][Full Text] [Related]
9. Cysteine 159 delineates a hinge region of the alternating access monocarboxylate transporter 1 and is targeted by cysteine-modifying inhibitors.
Köpnick AL; Geistlinger K; Beitz E
FEBS J; 2021 Oct; 288(20):6052-6062. PubMed ID: 33999492
[TBL] [Abstract][Full Text] [Related]
10. In Vivo Anticancer Activity of AZD3965: A Systematic Review.
Silva A; Antunes B; Batista A; Pinto-Ribeiro F; Baltazar F; Afonso J
Molecules; 2021 Dec; 27(1):. PubMed ID: 35011413
[TBL] [Abstract][Full Text] [Related]
11. In Vitro and In Vivo Efficacy of AZD3965 and Alpha-Cyano-4-Hydroxycinnamic Acid in the Murine 4T1 Breast Tumor Model.
Guan X; Morris ME
AAPS J; 2020 Jun; 22(4):84. PubMed ID: 32529599
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of monocarboxyate transporter 1 by AZD3965 as a novel therapeutic approach for diffuse large B-cell lymphoma and Burkitt lymphoma.
Noble RA; Bell N; Blair H; Sikka A; Thomas H; Phillips N; Nakjang S; Miwa S; Crossland R; Rand V; Televantou D; Long A; Keun HC; Bacon CM; Bomken S; Critchlow SE; Wedge SR
Haematologica; 2017 Jul; 102(7):1247-1257. PubMed ID: 28385782
[TBL] [Abstract][Full Text] [Related]
13. MCT1 Inhibitor AZD3965 Increases Mitochondrial Metabolism, Facilitating Combination Therapy and Noninvasive Magnetic Resonance Spectroscopy.
Beloueche-Babari M; Wantuch S; Casals Galobart T; Koniordou M; Parkes HG; Arunan V; Chung YL; Eykyn TR; Smith PD; Leach MO
Cancer Res; 2017 Nov; 77(21):5913-5924. PubMed ID: 28923861
[TBL] [Abstract][Full Text] [Related]
14. Monocarboxylate transporters (MCTs) in gliomas: expression and exploitation as therapeutic targets.
Miranda-Gonçalves V; Honavar M; Pinheiro C; Martinho O; Pires MM; Pinheiro C; Cordeiro M; Bebiano G; Costa P; Palmeirim I; Reis RM; Baltazar F
Neuro Oncol; 2013 Feb; 15(2):172-88. PubMed ID: 23258846
[TBL] [Abstract][Full Text] [Related]
15. Inhibition of monocarboxylate transporter-1 (MCT1) by AZD3965 enhances radiosensitivity by reducing lactate transport.
Bola BM; Chadwick AL; Michopoulos F; Blount KG; Telfer BA; Williams KJ; Smith PD; Critchlow SE; Stratford IJ
Mol Cancer Ther; 2014 Dec; 13(12):2805-16. PubMed ID: 25281618
[TBL] [Abstract][Full Text] [Related]
16. Basigin (CD147) is the target for organomercurial inhibition of monocarboxylate transporter isoforms 1 and 4: the ancillary protein for the insensitive MCT2 is EMBIGIN (gp70).
Wilson MC; Meredith D; Fox JE; Manoharan C; Davies AJ; Halestrap AP
J Biol Chem; 2005 Jul; 280(29):27213-21. PubMed ID: 15917240
[TBL] [Abstract][Full Text] [Related]
17. A Nonradioactive High-Throughput Screening-Compatible Cell-Based Assay to Identify Inhibitors of the Monocarboxylate Transporter Protein 1.
Bailey TL; Nieto A; McDonald PH
Assay Drug Dev Technol; 2019 Aug; 17(6):275-284. PubMed ID: 31532712
[No Abstract] [Full Text] [Related]
18. Preclinical Efficacy of the Novel Monocarboxylate Transporter 1 Inhibitor BAY-8002 and Associated Markers of Resistance.
Quanz M; Bender E; Kopitz C; Grünewald S; Schlicker A; Schwede W; Eheim A; Toschi L; Neuhaus R; Richter C; Toedling J; Merz C; Lesche R; Kamburov A; Siebeneicher H; Bauser M; Hägebarth A
Mol Cancer Ther; 2018 Nov; 17(11):2285-2296. PubMed ID: 30115664
[TBL] [Abstract][Full Text] [Related]
19. Treatment of
Follman KE; Morris ME
J Pharmacol Exp Ther; 2019 Jul; 370(1):84-91. PubMed ID: 31010842
[TBL] [Abstract][Full Text] [Related]
20. Polarized expression of monocarboxylate transporters in human retinal pigment epithelium and ARPE-19 cells.
Philp NJ; Wang D; Yoon H; Hjelmeland LM
Invest Ophthalmol Vis Sci; 2003 Apr; 44(4):1716-21. PubMed ID: 12657613
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]